Iceland· IS-EU/1/22/1646/001-003
Amifampridine SERB
A amifampridine product containing amifampridinum inn fosfat, registered in Iceland by SERB S.A.. The same ATC class is registered in 16 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Amifampridine is registered in 16 of 19 countries.
Countries holding a registration under ATC N07XX05 (amifampridine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Amifampridine · ATC N07XX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amifampridine costs, country by country.
Normalised to the WHO defined daily dose (40 mg), the median price runs from $75.59 in Switzerland to $3657.38 in France — a ×48 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amifampridine · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- FR France$3657.38
- CH Switzerland$75.59
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Amifampridinum INN fosfat
- Manufacturer
- SERB S.A.
- Country
- Iceland (IS)
- ATC code
- N07XX05
- ATC class
- Amifampridine
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for amifampridine.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amifampridine · interactions on record
82 records
- 4 severe
- 78 moderate
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- IohexolV08AB02severe
- IopamidolV08AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Amifampridine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAmifampridine Accord 10 mg tablettenAccord Healthcare B.V.
- United Kingdom3,4-Diaminopyridine 10mg tabletsSpecial Order
- CzechiaAMIFAMPRIDINE SERBSERB S.A., Brusel
- PolandAmifampridine Medical ValleyMedical Valley Invest AB
- FranceAMIFAMPRIDINE SERB 10 mg, compriméSERB (BELGIQUE)
- CanadaFIRDAPSEKYE PHARMACEUTICALS INC.
- FinlandAmifampridine SERBSERB S.A.
- IrelandAmifampridine SERB 10 mg tabletsSERB S.A.
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Germany · Amifampridin Accord, Amifampridin Amarox
- France · Amifampridine Amarox, Amifampridine Biogaran
- Hungary · Amifampridine Accord
- Italy · Amifampridina Accord
- Liechtenstein · Amifampridine Serb, Firdapse
- Netherlands · Amifampridine Accord, Amifampridine Amarox
- Norway · Amifampridin Medical Valley, Amifampridine Accord
- Poland · Amifampridine Medical Valley
- Portugal · Amifampridina Accord, Amifampridina Generis
- Slovenia · Amifampridin Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/90c3f786-dea0-4acf-92d7-1e654f936ab8 GET /v1/drugs/90c3f786-dea0-4acf-92d7-1e654f936ab8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tafla",
"source": "lyfjastofnun",
"atc_raw": "N07XX05",
"marketed": false,
"strength": "10 mg",
"ma_number": "EU/1/22/1646/001-003",
"substance": "Amifampridinum INN fosfat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í taugasjúkdómum og sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44700"
}See everything about amifampridine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.